Literature DB >> 15692443

[EBV-associated cutaneous plasmocytoma in a renal transplant patient].

A Carbonnelle1, E Mahé, E Morelon, B Varet, H Kreis, N Brousse, S Fraitag.   

Abstract

INTRODUCTION: Postransplant lymphoproliferative disorders are well known complications of solid organ transplant, usually associated with Epstein-Barr virus (EBV). OBSERVATION: A 25 year old renal transplant patient presented with two subcutaneous nodules on the lower limb that appeared 3 years after a second renal transplantation. Biopsy of one nodule showed an EBV associated plasmocytoma located in the subcutaneous tissue. A complete systemic evaluation showed no evidence of extracutaneous involvement. The patient was treated with anti CD20 therapy (rituximab), and complete remission was achieved. DISCUSSION: Extranodular localisations of postransplant lymphoproliferative disorders are usually reported, but cutaneous localizations are rarely described. Histological presentation are various, but plasmocytoma-type is infrequent. Initial therapy of cutaneous EBV-associated postransplant lymphoproliferative disorders without extracutaneous involvement consists in reduction of the immunosuppression therapy and/or an antiviral treatment and prolonged surveillance. Treatment with monoclonal anti-CD20 antibodies (rituximab) is proposed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15692443     DOI: 10.1016/s0151-9638(04)93845-8

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  1 in total

Review 1.  Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.

Authors:  Raphaël Kormann; Hélène François; Thibault Moles; Jacques Dantal; Nassim Kamar; Karine Moreau; Thomas Bachelet; Anne-Elisabeth Heng; Antoine Garstka; Charlotte Colosio; Didier Ducloux; Johnny Sayegh; Benjamin Savenkoff; Denis Viglietti; Rebecca Sberro; Eric Rondeau; Julie Peltier
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.